Careful buying this stock btw. Could get quite volatile if there is a delay in ramping up revenue. It might take a while as a lot of people might be very used to their current treatment. I started small, and will add if it goes below $1 which it very well could if Q1 is weak.
Interesting observation published in journal of int Urology and Nephrology
https://stocktwits.com/milt0n/message/570185331
Careful buying this stock btw. Could get quite volatile if there is a delay in ramping up revenue. It might take a while as a lot of people might be very used to their current treatment. I started small, and will add if it goes below $1 which it very well could if Q1 is weak.